Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
zipalertinib + glumetinib
- Development stage
- Unknown
- Lead developer
- Taiho Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
TAS6417 + SCC244 is a combination therapy consisting of zipalertinib (TAS6417) and glumetinib (SCC244), currently under clinical investigation by Taiho Pharmaceutical for the treatment of non-small cell lung cancer (NSCLC). Zipalertinib is an orally available, irreversible small molecule inhibitor of EGFR, specifically designed to target exon 20 insertion mutations while maintaining selectivity over wild-type EGFR. Glumetinib is a potent, highly selective small molecule inhibitor of the MET receptor tyrosine kinase. This combination is intended to overcome resistance in EGFR-mutated NSCLC, particularly cases where MET amplification or activation drives tumor progression or resistance to standard EGFR inhibitors.
- Other names
- TAS6417 + SCC244zipalertinib + glumetinibCLN-081 + SCC244
02
Targets
EGFR ex20ins (Epidermal growth factor receptor exon 20 mutant)MET (Mesenchymal-epithelial transition factor receptor)
Beyond the preview
Go deeper on zipalertinib + glumetinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on zipalertinib + glumetinib.